Fig. 4
Guadecitabine modifies TME by increasing macrophages, while Guadecitabine/ICBs skews TAM to M1 subset, without upregulating alternative immune checkpoint. A identification of Treg (CD45+CD3+ CD4+CD25+Foxp3+), and MDSC (CD45+CD11b+Ly6C+/-Ly6G+/-) and subset M (Ly6C+Ly6G-) G (Ly6ClowLy6G+) on CD45+ cells infiltrating tumors. B frequencies of macrophages (Ly6C-Ly6G- on CD45+CD3-CD19-NKp46-I-Ab-CD11c-/+) and identification of TAM subsets: M0 CD38-Egr2-, M1 CD38+Egr2-, M2 CD38-Egr2+. *p<0.05, **p<0.02, ***p<0.01